| Title |
Effect of a herbal extract powder (YY-312) from Imperata cylindrica Beauvois, Citrus unshiu Markovich, and Evodia officinalis Dode on body fat mass in overweight adults: a 12-week, randomized, double-blind, placebo-controlled, parallel-group clinical trial. |
| Authors |
Cho YG, Jung JH, Kang JH, Kwon JS, Yu SP, Baik TG. |
| Journal |
BMC Complement Altern Med. |
| Year |
2017 |
| Vol (Issue) |
17(1) |
| Page |
375. |
| doi |
10.1186/s12906-017-1871-4. |
| PMID |
28754119 |
| Url |
http://www.ncbi.nlm.nih.gov/pubmed/28754119 |
| MeSH |
Adipose Tissue/metabolism*
Adult
Body Composition/drug effects
Body Weight/drug effects
Citrus*
Double-Blind Method
Evodia*
Female
Humans
Male
Middle Aged
Obesity/drug therapy*
Obesity/metabolism
Overweight
Phytotherapy*
Plant Extracts/pharmacology
Plant Extracts/therapeutic use*
Poaceae*
Waist Circumference/drug effects |
| Keywords |
Anti-obesity agents; Citrus unshiu Markovich; Evodia officinalis Dode; Imperata cylindrica Beauvois; Overweight; Weight loss |
| 한글 키워드 |
항비만제; 진피; 오수유; 백모근; 과체중; 체중 감소 |
KMCRIC
Summary & Commentary |
KMCRIC 비평 보기 + |
| Korean Study |
Y |
| Abstract |
BACKGROUND:
YY-312 is a herbal extract powder from Imperata cylindrica Beauvois, Citrus unshiu Markovich, and Evodia officinalis Dode, which have health promoting effects, including body fat reduction. We aimed to evaluate the efficacy and safety of YY-312 for body fat reduction in overweight adults.
METHODS:
This was a 12-week, randomized, double-blind, placebo-controlled, parallel-group clinical trial performed in overweight Korean adults aged 19-60 years with a body mass index of 25.0-29.9 kg/m2. The daily dose of YY-312 was 2400 mg (containing 1800 mg of active herbal extract and 600 mg of cyclodextrin). Primary outcomes were reductions in body fat mass (BFM) and body fat percentage (BF%) after 12 weeks. Secondary outcomes included reductions in body weight and waist circumference (WC) after 12 weeks.
RESULTS:
After 12 weeks, BFM (1.6 kg vs. 0.1 kg; P = 0.023) and BF% (1.5% vs. -0.2%; P = 0.018) decreased significantly more in the YY-312 group than in the placebo group, as did body weight (2.7 kg vs. 1.0 kg; P = 0.014) and WC (2.2 cm vs. 0.8 cm; P = 0.049). All safety parameters were within normal limits; no serious adverse events occurred in either group.
CONCLUSIONS:
In a 12-week clinical trial in overweight adults, YY-312 resulted in significantly greater reduction in body fat vs. placebo, while being safe and well tolerated.
|
| 국문초록 |
|
| Language |
영어 |
| 첨부파일 |
|
